Scholar Rock Advances Apitegromab Phase 3 BLA and Bolsters Pipeline

Company Overview

Scholar Rock Holding Corporation (NASDAQ: SRRK) is a clinical-stage biopharmaceutical company founded in 2012. The firm utilizes a proprietary platform to discover, develop, and deliver monoclonal antibody therapies that selectively target latent forms of protein growth factors. The company's focus includes treatments for neuromuscular disorders, cancer, fibrotic diseases, and iron-restricted anemia.

Corporate Structure and Leadership

Scholar Rock employs between 51 and 200 people and is headquartered in Cambridge, Massachusetts. The management team consists of executives with experience in research, clinical development, and regulatory affairs. The company’s board and leadership combine expertise in translational science, business development, and commercialization.

Biopharmaceuticals by little plant

Recent Developments and Pipeline

Scholar Rock has a diversified pipeline of investigational therapies targeting high-unmet-need conditions:

• Apitegromab (Phase 3; selective anti-latent myostatin antibody)
– Indicated for Spinal Muscular Atrophy: anticipated Biologics License Application (BLA) submission in 2025 and commercial launch in 2025, pending regulatory approval.

• SRK-439 (preclinical; novel anti-latent myostatin antibody)
– Indicated for rare neuromuscular disorders: aiming to file an Investigational New Drug (IND) application in the second half of 2025.

• SRK-181 (Phase 1; selective anti-latent TGF β1)
– Indicated for locally advanced or metastatic solid tumors: rolling clinical data updates are currently in progress.

• SRK-373 (preclinical; context-dependent anti-latent TGF β1)
– Indicated for fibrotic diseases: IND-enabling studies are ongoing.

• SRK-256 (preclinical; selective anti-RGMc/HJV)
– Indicated for iron-restricted anemia: IND-enabling studies are also in progress.

In addition to internal programs, Scholar Rock entered a strategic collaboration with Gilead Sciences on December 19, 2018, to develop inhibitors of latent TGF β activation for fibrotic diseases.

Financial and Strategic Analysis

As of December 9, 2025, SRRK shares closed at $45.50, representing an increase of 0.55% on a trading volume of 330,764 shares compared to an average daily volume of 163 shares. Key financial metrics (trailing twelve months) include:

• Market capitalization: approximately $4.6 billion
• EPS (TTM): –$3.15
• Net loss: –$353.4 million
• Total cash (most recent quarter): $369.6 million
• Total debt/equity (most recent quarter): 44.9%
• Levered free cash flow (TTM): –$146.9 million

The company’s cash position and access to capital markets support continued investment in its pipeline. The partnership model, illustrated by the Gilead agreement, provides external validation and distributes risk for selected programs.

Market Position and Industry Context

Scholar Rock operates within the biotechnology sector, focusing on innovative approaches to protein growth-factor modulation. Its therapeutic areas—neuromuscular disorders, oncology, fibrosis, and anemia—are characterized by high unmet needs and ongoing clinical development by competitors. The company’s stock demonstrates a beta of 0.62 over five years, indicating lower volatility relative to broader market trends. Scholar Rock’s selective action mechanism differentiates it from platforms that neutralize activated proteins instead of preventing activation.

tl;dr

As of December 9, 2025, SRRK shares trade at $45.50 (+0.55%). Apitegromab is in Phase 3 with a BLA submission and launch anticipated for 2025. SRK-439 plans an IND filing in 2H 2025. Preclinical programs SRK-181, SRK-373, and SRK-256 are making progress toward clinical milestones. The company’s cash position supports pipeline advancement and potential future partnerships.